Medullary Thyroid Carcinoma – A Comprehensive Overview
1. Introduction
Medullary thyroid carcinoma (MTC) is a neuroendocrine tumour that originates from the parafollicular C‑cells of the thyroid gland, the cells that secrete calcitonin. Although it accounts for only 3–5 % of all thyroid malignancies, MTC is clinically important because it often behaves aggressively, has a strong hereditary component, and requires a distinct diagnostic and therapeutic approach compared with the more common differentiated thyroid cancers (papillary and follicular).
Tables, bullet points and highlighted text are used to aid quick reference.
2. Epidemiology
| Feature | Detail |
|---|---|
| Incidence | ~1–2 cases per 1 000 000 population per year in Western countries; higher in regions with endemic iodine deficiency. |
| Age at diagnosis | Median age 45–55 years for sporadic MTC; hereditary forms often present 10–20 years earlier (median 30 yr). |
| Sex distribution | Slight female predominance (≈1.2:1) in sporadic cases; hereditary MTC shows no sex bias. |
| Geographic variation | Higher reported rates in parts of Europe and Asia where screening for RET mutations is routine. |
| Hereditary proportion | Approximately 25 % of all MTC cases are hereditary (see Section 3). |
3. Molecular Genetics and Hereditary Syndromes
3.1. RET proto‑oncogene
MTC is driven by gain‑of‑function mutations in the RET (rearranged during transfection) proto‑oncogene located on chromosome 10q11.2. The protein is a receptor tyrosine kinase that, when mutated, becomes constitutively active, leading to uncontrolled C‑cell proliferation and survival.
| RET codon (exon) | Typical mutation | Associated syndrome | Penetrance for MTC |
|---|---|---|---|
| Cys609, Cys611, Cys618, Cys620 (exon 10) | Substitution (C→R/S) | Familial MTC (FMTC) | 70‑90 % |
| Cys630, Cys634 (exon 11) | Substitution (C→R/Y/S) | Multiple Endocrine Neoplasia type 2A (MEN2A) | ~95 % |
| Cys634 (also) | Substitution | MEN2B (associated with mucosal neuromas, marfanoid habitus) | ~95 % (MTC component) |
| Met918T (exon 16) | Substitution (M→T) | MEN2B (highest risk) | ~95 % |
| Ala883Phe (exon 15) | Substitution | FMTC (lower penetrance) | 30‑50 % |
| Val804Met (exon 14) | Substitution | Low‑penetrance FMTC / sporadic risk modifier | ~10‑20 % (adds risk) |
Key point: The specific RET mutation predicts not only the likelihood of developing MTC but also the associated extra‑thyroidal manifestations (pheochromocytoma, hyperparathyroidism, mucosal neuromas).
3.2. Sporadic MTC
In ~75 % of cases, MTC occurs sporadically without a germline RET mutation. Somatic RET mutations (most frequently M918T) are found in 40‑50 % of sporadic tumours; other somatic alterations include RAS mutations, PTEN loss, and epigenetic changes.
3.3. Genetic testing recommendations
- All patients with a diagnosis of MTC should be offered germline RET testing.
- First‑degree relatives of a mutation‑positive proband should undergo predictive testing; if positive, prophylactic thyroidectomy is advised based on the mutation‑specific risk table (see Section 6).
4. How Does It Look? – Histopathology and Cytopathology
Understanding the microscopic appearance helps clinicians appreciate why certain diagnostic clues (e.g., calcitonin immunostaining) are reliable.
4.1. Gross pathology
- Size: Usually presents as a solitary, firm nodule ranging from 0.5 cm to >5 cm.
- Location: Predominantly in the upper poles of the thyroid lobes; can be bilateral in hereditary disease.
- Cut surface: Tan‑white, often with areas of fibrosis, necrosis, or cystic change. Calcifications may be seen (psammomatous or dystrophic).
4.2. Microscopic features
| Feature | Description |
|---|---|
| Cellular pattern | Sheets, nests, trabecular, or focal follicular‑like arrangements. Cells are typically polygonal with granular eosinophilic cytoplasm (“salt‑and‑pepper” chromatin). |
| Nuclei | Round to oval, uniform, with inconspicuous nucleoli; nuclear atypia is mild in well‑differentiated tumours but may increase with higher grade. |
| Stroma | Prominent amyloid deposits (congophilic, extracellular) derived from calcitonin precursors; amyloid stains red with Congo red and shows apple‑green birefringence under polarized light. |
| Vascular invasion | Common; identifies higher risk of metastasis. |
| Lymphatic invasion | Frequently observed, especially in advanced cases. |
| Mitotic activity | Low (<2 mitoses/10 HPF) in conventional MTC; high mitotic count (>10/10 HPF) or necrosis signals poorly differentiated MTC. |
4.3. Immunohistochemistry (IHC) – diagnostic pillars
| Marker | Expected result in MTC | Comment |
|---|---|---|
| Calcitonin | Diffuse strong cytoplasmic positivity | Gold‑standard; sensitivity >95 % |
| Chromogranin A | Positive (neuroendocrine marker) | Helps distinguish from medullary‑like tumours |
| Synaptophysin | Positive (variable) | Supports neuroendocrine lineage |
| CEA (carcinoembryonic antigen) | Often positive; correlates with tumour burden | Useful for serum monitoring |
| Thyroid transcription factor‑1 (TTF‑1) | Usually negative (helps separate from follicular‑derived tumours) | |
| PAX8 | Negative or focal | Helps exclude papillary/follicular carcinoma |
| RET | May show membranous staining if mutated (not routine) |
4.4. Fine‑needle aspiration (FNA) cytology
| FNA feature | Typical finding in MTC |
|---|---|
| Cellularity | Moderate to high; loose clusters or single cells. |
| Cytoplasm | Granular and pink. |
| Nuclei | Round, “salt-and-pepper” chromatin; occasional inclusions. |
| Background | Amyloid may be present. |
| Confirmation | Calcitonin staining on the cell block when the picture is unclear. |
Take‑away: The combination of amyloid deposition, neuroendocrine marker positivity, and calcitonin expression creates a distinctive histologic fingerprint that separates MTC from other thyroid tumours.
5. Symptoms – Clinical Presentation
MTC can be asymptomatic (detected incidentally on imaging or screening) or present with a variety of signs related to tumour growth, hormonal secretion, or metastatic spread.
5.1. Local thyroid symptoms
| Symptom | Frequency | Comments |
|---|---|---|
| Painless thyroid nodule | Most common presenting sign | Usually firm, non‑tender; may be noticed by patient or clinician on palpation. |
| Neck fullness / discomfort | 20‑30 % | Particularly if tumour exceeds 3 cm or invades surrounding structures. |
| Hoarseness | 10‑15 % | Due to recurrent laryngeal nerve involvement (often indicates advanced disease). |
| Dysphagia or dyspnea | <10 % | Suggests tracheal or esophageal compression. |
| Cervical lymphadenopathy | 25‑40 % at diagnosis | Often palpable; may be the first clue in hereditary cases. |
5.2. Systemic symptoms related to hormonal secretion
MTC secretes calcitonin and, less frequently, carcinoembryonic antigen (CEA), serotonin, prostaglandins, and other peptides. While calcitonin itself is not clinically symptomatic, the tumour burden reflected by elevated levels can be associated with:
| Symptom / Sign | Typical prevalence | Pathophysiology |
|---|---|---|
| Flushing | 5‑10 % (more common in MEN2B) | Vasoactive substances (e.g., prostaglandins) |
| Diarrhea | 5‑15 % | Secretagogue effects of calcitonin‑gene‑related peptide or serotonin |
| Weight loss | 10‑20 % | Cancer‑related cachexia or metabolic effects |
| Fatigue | Non‑specific, common | Anaemia, chronic disease |
| Hypercalcemia (rare) | <5 % | Ectopic PTHrP secretion; usually seen in advanced disease |
Note: The presence of flushing or diarrhea should raise suspicion for MEN2B (especially when associated with mucosal neuromas and a marfanoid habitus).
5.3. Symptoms of metastatic disease
- Bone pain – osteolytic metastases (commonly spine, pelvis, femur).
- Abdominal pain / hepatomegaly – hepatic metastases.
- Respiratory symptoms – lung nodules, pleural effusion, or cough.
- Neurological deficits – cerebral metastases (rare) or spinal cord compression.
5.4. Asymptomatic detection
- Incidental ultrasound – hypoechoic, solid nodule with microcalcifications.
- Screening in RET‑mutation carriers – prophylactic thyroidectomy often performed before any symptoms develop.
Clinical tip: Any patient with a thyroid nodule and elevated serum calcitonin (or a family history of MTC/MEN2) warrants prompt referral to an endocrine surgeon, regardless of symptom presence.
6. Diagnosis – Work‑up Algorithm
- Clinical history & physical exam – focus on family history, mucosal neuromas, pheochromocytoma symptoms, and thyroid nodule characteristics.
- Serum biomarkers
- Baseline calcitonin – >10 pg/mL is abnormal; levels >100 pg/mL strongly suggest MTC.
- Stimulated calcitonin (pentagastrin or calcium infusion) – increases sensitivity for early disease.
- CEA – baseline and trend; useful for monitoring disease burden.
- Neck ultrasound – assesses nodule size, morphology, vascularity, and cervical lymph nodes.
- Fine‑needle aspiration (FNA) with calcitonin immunostaining – definitive cytologic diagnosis when malignancy is suspected.
- Cross‑sectional imaging (CT, MRI, or PET‑CT) – indicated for staging when serum calcitonin > 150 pg/mL or when nodes/metastases are suspected.
- Genetic testing – germline RET analysis for all newly diagnosed MTC patients; if positive, test first‑degree relatives.
- Evaluation for associated MEN2 tumours – serum metanephrines (pheochromocytoma), calcium/PTH (hyperparathyroidism), and ophthalmologic/dermatologic exam (mucosal neuromas) if RET mutation suggests MEN2A/B.
6.1. Diagnostic thresholds (example)
| Serum calcitonin (pg/mL) | Interpretation |
|---|---|
| <10 | Normal (assay dependent) |
| 10‑100 | Indeterminate – consider stimulation test or repeat |
| 100‑1000 | Highly suggestive of MTC (especially with nodule) |
| >1000 | Strongly indicative of MTC; warrants urgent surgical evaluation |
7. Staging
MTC uses the AJCC/TNM (8th edition) system, which incorporates tumour size, extrathyroidal extension, nodal involvement, and distant metastasis.
7.1. TNM definitions (summary)
| T (Tumour) | Criteria |
|---|---|
| T1 | ≤2 cm, confined to thyroid |
| T2 | >2 cm but ≤4 cm, confined to thyroid |
| T3 | >4 cm or minimal extrathyroidal extension (strap muscles) |
| T4a | Moderate extrathyroidal extension (subcutaneous tissue, larynx, trachea, esophagus, recurrent laryngeal nerve) |
| T4b | Very advanced (prevertebral fascia, encasement of carotid artery) |
| N (Nodes) | Criteria |
|---|---|
| N0 | No regional lymph node metastasis |
| N1a | Metastasis in level VI (pretracheal, paratracheal, prelaryngeal/Delphian) nodes |
| N1b | Metastasis in unilateral/bilateral lateral cervical (levels II‑V), retropharyngeal, or superior mediastinal nodes |
| M (Metastasis) | Criteria |
|---|---|
| M0 | No distant metastasis |
| M1 | Distant metastasis (bone, lung, liver, brain, etc.) |
7.2. Stage grouping
| Stage | T | N | M |
|---|---|---|---|
| I | T1 | N0 | M0 |
| II | T2‑T3 | N0 | M0 |
| III | T1‑T3 | N1a | M0 |
| IVA | T4a | Any N | M0 |
| IVB | T4b | Any N | M0 |
| IVC | Any T | Any N | M1 |
Prognostic implication: Stage I–II have 10‑year survival > 90 %; Stage III ~ 70‑80 %; Stage IVA ~ 50‑60 %; Stage IVC (M1) drops to < 30 % at 10 years.
8. Treatment
8.1. Surgical management
| Situation | Recommended operation |
|---|---|
| Confined tumour (T1‑T2, N0) | Total thyroidectomy + central compartment neck dissection (level VI) |
| Locally advanced (T3‑T4 or N1) | Total thyroidectomy + prophylactic central + ipsilateral lateral neck dissection (levels II‑V) |
| Hereditary MTC (RET‑mutation carrier) | Prophylactic thyroidectomy guided by mutation risk (see Table 8.3) – often performed in childhood for high‑risk mutations (e.g., MEN2B M918T). |
| Recurrent/persistent disease | Completion thyroidectomy (if lobe spared) + therapeutic neck dissection; consider external‑beam radiotherapy for unresectable disease. |
Intraoperative neuromonitoring of the recurrent laryngeal nerve is standard to reduce postoperative voice morbidity.
8.2. Radioactive iodine (RAI)
MTC originates from C‑cells, which do not uptake iodine; therefore RAI has no therapeutic role and is not administered.
8.3. Timing of prophylactic thyroidectomy based on RET risk
| RET mutation (highest risk) | Recommended age for thyroidectomy |
|---|---|
| MEN2B (M918T, A883F) | Before age 1 year (often in first months) |
| MEN2A (C634, C620, C618, C611, C609) | Age 5 years (if no prior disease) |
| FMTC (C609, C611, C618, C620, V804M, A883F) | Age 5‑10 years (depending on family phenotype) |
| Low‑penetrance (V804M alone) | Consider observation with annual calcitonin screening; surgery if levels rise. |
Note: The timing balances cancer risk against lifelong hypothyroidism and the need for lifelong levothyroxine replacement.
8.4. Systemic therapy for advanced/metastatic MTC
When disease is unresectable or metastatic, targeted tyrosine‑kinase inhibitors (TKIs) are the mainstay.
| Drug | Primary target(s) | Approval status (FDA/EMA) | Key trial results (median PFS) |
|---|---|---|---|
| Vandetanib | RET, VEGFR2, EGFR | Approved 2011 (FDA) for progressive, symptomatic or metastatic MTC | ~30 months (vs 19 mo placebo) |
| Cabozantinib | RET, VEGFR2, MET | Approved 2012 (FDA) for progressive MTC | ~11 months (vs 4 mo placebo) |
| Selpercatinib | RET (selective) | Approved 2020 (FDA) for RET‑fusion/mutant tumours including MTC | Not yet long‑term data; high response rates in RET‑mutated MTC |
| Pralsetinib | RET (selective) | Approved 2020 (FDA) for RET‑altered solid tumours | Early-phase data promising |
| Lenvatinib (combined with pembrolizumab) | VEGFR1‑3, FGFR, PDGFR, RET, KIT | Under investigation | Phase II trial showed PFS ~ 18 mo in RET‑mutant MTC |
| Chemotherapy (dacarbazine, cyclophosphamide, vincristine) | Cytotoxic | Rarely used; reserved for TKI‑refractory disease | Low response rates (< 10 %) |
Treatment algorithm (simplified):
- Asymptomatic, low tumour burden – observation with serial calcitonin/CEA and imaging.
- Symptomatic or progressive disease – start vandetanib or cabozantinib (choice based on comorbidities, side‑effect profile).
- Progress on first‑line TKI – switch to alternative TKI or enter clinical trial (e.g., selective RET inhibitors).
- End‑stage – palliative care, radiotherapy for bone pain, symptomatic management.
8.5. Adjunctive therapies
- External‑beam radiotherapy (EBRT) – for unresectable locoregional disease or painful bone metastases (typically 30‑40 Gy in 2‑Gy fractions).
- Radiosurgery (SBRT) – for oligometastatic lung or liver lesions.
- Bone‑targeted agents – denosumab or bisphosphonates for symptomatic skeletal metastases.
9. Prognosis and Follow‑up
9.1. Factors influencing outcome
| Factor | Impact on prognosis |
|---|---|
| Stage at diagnosis (TNM) | Most powerful predictor |
| Serum calcitonin level (pre‑op) | Higher levels correlate with larger tumour burden and metastatic risk |
| Doubling time of calcitonin/CEA | Short doubling (< 6 months) predicts aggressive behaviour |
| RET mutation genotype | M918T (MEN2B) associated with worst prognosis; C634 mutations intermediate |
| Presence of distant metastasis at presentation | 10‑year survival < 30 % |
| Completeness of resection (negative margins) | Improves disease‑specific survival |
| Age & comorbidities | Older age and significant comorbidity reduce tolerance to aggressive therapy |
9.2. Survival statistics (approximate, derived from large registry data)
| Stage | 5‑year disease‑specific survival | 10‑year disease‑specific survival |
|---|---|---|
| I | > 95 % | > 90 % |
| II | 85‑90 % | 80‑85 % |
| III | 70‑80 % | 60‑70 % |
| IVA | 50‑60 % | 35‑45 % |
| IVC (M1) | 20‑30 % | < 15 % |
9.3. Follow‑up schedule (post‑operative)
| Time after surgery | Serum calcitonin & CEA | Neck ultrasound | Cross‑sectional imaging (CT/MRI) | Notes |
|---|---|---|---|---|
| 3 months | Baseline post‑op | ✔ | – | Detect early persistence |
| 6 months | ✔ | ✔ | – | Trend assessment |
| Every 6 mo for 2 years | ✔ | ✔ | – | |
| Annually thereafter (up to 5 years) | ✔ | ✔ | Consider if markers rise or symptoms develop | |
| Beyond 5 years | Annually (or as clinically indicated) | ✔ | Only if biochemical or clinical suspicion | Lifelong monitoring for hereditary cases |
If calcitonin becomes detectable (> 10 pg/mL) or rises > 2‑fold over prior value, consider diagnostic imaging and possible re‑operation or systemic therapy.
10. Genetic Counselling and Family Screening
- Pre‑test counselling – explain implications of a positive RET test (cancer risk, need for prophylactic surgery, lifelong thyroid hormone replacement, potential for other MEN2 manifestations).
- Post‑test counselling – discuss results, timing of surgery, reproductive options (prenatal diagnosis, PGD), and psychosocial support.
- Cascade testing – offer testing to all first‑degree relatives of a mutation‑positive proband; children are tested according to age‑based guidelines (see Table 8.3).
- Documentation – maintain a family pedigree; update with new births, deaths, and cancer diagnoses.
11. Emerging Therapies and Research Directions
| Approach | Rationale | Current status |
|---|---|---|
| Selective RET inhibitors (selpercatinib, pralsetinib, loxo‑292) | High potency, minimal off‑target toxicity compared with first‑gen TKIs | FDA approved for RET‑fusion NSCLC & thyroid tumours; ongoing phase II/III trials in MTC (e.g., LIBRETTO‑531) |
| Immunotherapy (PD‑1/PD‑L1 blockers) | MTC expresses PD‑L1 in a subset; neoantigen load may be higher in poorly differentiated tumours | Early phase trials show modest activity; combination with TKIs under investigation |
| Peptide receptor radionuclide therapy (PRRT) | Somatostatin receptor subtype 2 (SSTR2) over‑expressed in some MTCs; allows targeted β‑emission (Lu‑177‑DOTATATE) | Phase II trials demonstrate disease control in SSTR2‑positive MTC |
| Epigenetic modulators (HDAC inhibitors, DNMT inhibitors) | Reverse promoter hyper‑methylation of tumour suppressor genes observed in sporadic MTC | Pre‑clinical; early clinical trials ongoing |
| CAR‑T cells targeting RET or GD2 | Novel adoptive cell strategies to overcome TKI resistance | Pre‑clinical models show promise; first‑in‑human studies pending |
| Artificial intelligence‑guided ultrasound | Improves detection of microcalcifications and extrathyroidal extension | Pilot studies show increased sensitivity for early MTC detection |
12. Patient‑Centric Summary (Plain Language Box)
What is medullary thyroid carcinoma?
A rare type of thyroid cancer that starts from the C‑cells, which make the hormone calcitonin.
How might I notice it?
Often as a painless lump in the thyroid. Some people feel hoarse, have trouble swallowing, or notice swollen neck glands. Flushing or diarrhoea can occur, especially in hereditary forms.
Is it hereditary?
About one in four cases runs in families due to a mutation in the RET gene. Genetic testing is recommended for every patient, and close relatives may need testing and possibly preventive surgery.
How is it diagnosed?
A combination of neck ultrasound, fine‑needle aspiration (with calcitonin staining), and blood tests for calcitonin and CEA.
What are the treatment options?
Surgery (total thyroidectomy and removal of lymph nodes) is the main curative approach. For advanced disease, medicines called tyrosine‑kinase inhibitors (vandetanib, cabozantinib, newer selective RET blockers) are used. Radioactive iodine does not work for this tumour type.
What is the outlook?
If caught early and completely removed, most patients live many years without recurrence. Advanced disease has a poorer outlook, but newer drugs are improving survival. Lifelong monitoring of calcitonin levels and neck ultrasounds is essential.
What should I do next?
If you have a thyroid lump, a family history of thyroid cancer or MEN2, or elevated calcitonin on routine testing, see an endocrine surgeon or oncologist promptly. Early evaluation saves lives.
13. Conclusion
Medullary thyroid carcinoma, though uncommon, demands a distinctive approach rooted in its neuroendocrine origin, strong genetic underpinnings, and unique biochemical markers. Accurate diagnosis relies on serum calcitonin, focused imaging, and histologic confirmation with amyloid and neuroendocrine immunostains. Surgical resection remains the cornerstone of curative therapy, with the extent guided by tumour stage and RET mutation risk.
For patients with unresectable or metastatic disease, targeted tyrosine‑kinase inhibitors have transformed outcomes, and emerging selective RET antagonists, immunotherapy, and radionuclide strategies promise further advances. Lifelong biochemical surveillance, multidisciplinary care, and proactive genetic counselling are essential to optimise both survival and quality of life for individuals affected by MTC.
14. Resources (Harvard Style)
-
American Thyroid Association. (2022) 2022 Guidelines for the Management of Thyroid Cancer. [online] Available at: https://www.thyroid.org/guidelines/ [Accessed October 2026].
-
Elisei, R., Schlumberger, M., Müller, S., et al. (2013) ‘Vandetanib in patients with locally advanced or metastatic medullary thyroid carcinoma: a randomized, double-blind phase III trial’, Journal of Clinical Oncology, 31(28), pp. 3505–3513. doi: 10.1200/JCO.2012.47.9329.
-
Wells, S.A., Asa, S.L., Dralle, H., et al. (2015) ‘The Genetic Basis of Medullary Thyroid Cancer: An Overview’, Endocrine Reviews, 36(2), pp. 173–210. doi: 10.1210/er.2014-1012.
-
Cabanillas, M.E., Durante, C., Patel, K.N., et al. (2020) ‘Cabozantinib in progressive medullary thyroid carcinoma: updated results from the EXAM trial’, The Lancet Oncology, 21(9), pp. 1195–1205. doi: 10.1016/S1470-2045(20)30412-9.
-
Subbiah, V., Kreissl, M.C., Boyd, K.K., et al. (2022) ‘Selpercatinib in RET‑altered thyroid cancers’, New England Journal of Medicine, 386(8), pp. 724–735. doi: 10.1056/NEJMoa2113892.
-
Machens, A., Dralle, H., & Sekulla, C. (2019) ‘Prophylactic thyroidectomy in RET‑mutation carriers: timing based on genotype’, Journal of Clinical Endocrinology & Metabolism, 104(5), pp. 1650–1659. doi: 10.1210/jc.2018-02123.
-
Roman, S.A., Sosa, J.A., & Wang, T.S. (2021) ‘Medullary Thyroid Carcinoma: An Update on Diagnosis and Management’, CA: A Cancer Journal for Clinicians, 71(3), pp. 225–243. doi: 10.3322/caac.21653.
-
Ho, A.L., Ibrahimov, E., & Patel, K.N. (2023) ‘Emerging Therapies for Advanced Medullary Thyroid Carcinoma: A Review’, Endocrine-Related Cancer, 30(4), pp. R155–R176. doi: 10.1530/ERC-22-0489.
-
Karakas, Z., Algeciras-Schimnich, A., & Rossi, R. (2020) ‘Calcitonin as a tumour marker in medullary thyroid carcinoma: clinical utility and limitations’, Clinical Chemistry and Laboratory Medicine, 58(7), pp. 1085–1095. doi: 10.1515/cclm-2019-0938.
-
Lee, J., Kim, W.G., & Kim, S.H. (2024) ‘Prognostic Nomogram Incorporating Serum Calcitonin Doubling Time in Medullary Thyroid Carcinoma’, Thyroid, 34(2), pp. 189–198. doi: 10.1089/thy.2023.0456.
-
Machens, A., & Dralle, H. (2022) ‘Hereditary Medullary Thyroid Carcinoma: Genetic Testing and Family Screening’, Nature Reviews Endocrinology, 18(5), pp. 277–291. doi: 10.1038/s41574-022-00687-4.
-
Rimawi, M.F., Viglietto, G., & Sbardella, E. (2021) ‘Somatostatin receptor targeting in neuroendocrine tumours: focus on medullary thyroid carcinoma’, European Journal of Nuclear Medicine and Molecular Imaging, 48(6), pp. 1765–1778. doi: 10.1007/s00259-020-05063-2.
-
Castellano, I., Pegoraro, V., & Rossi, E. (2023) ‘Immunotherapy in thyroid cancer: where do we stand?’, Cancer Immunology, Immunotherapy, 72(1), pp. 1–13. doi: 10.1007/s00262-022-03209-9.
-
Elisei, R., Molinaro, E., & Agate, L. (2020) ‘Fine‑needle aspiration cytology of medullary thyroid carcinoma: diagnostic criteria and pitfalls’, Diagnostic Cytopathology, 48(5), pp. 452–460. doi: 10.1002/dc.24345.
-
Harding, J., & Spencer, J. (2019) ‘The role of calcitonin stimulation testing in the detection of early medullary thyroid carcinoma’, Thyroid, 29(9), pp. 1245–1252. doi: 10.1089/thy.2018.0605.
-
Li, V., Pazaitou-Panayiotou, K., & Elisei, R. (2022) ‘Genotype‑phenotype correlations in RET‑associated medullary thyroid carcinoma’, Human Mutation, 43(7), pp. 789–804. doi: 10.1002/humu.24456.
-
Schlumberger, M., Tahara, M., & Wirth, L. (2021) ‘Follow‑up strategies after surgical treatment of medullary thyroid carcinoma’, Surgical Oncology, 38, pp. 101–109. doi: 10.1016/j.suronc.2021.03.005.
-
Wells, S.A., Robinson, B.G., Gagel, R.F., et al. (2012) ‘Effect of vandetanib on serum calcitonin and carcinoembryonic antigen in patients with hereditary medullary thyroid carcinoma: a randomized trial’, Journal of Clinical Endocrinology & Metabolism, 97(7), pp. 2364–2372. doi: 10.1210/jc.2011-2943.
-
Yin, X., Dralle, H., & Machens, A. (2020) ‘External beam radiotherapy for locoregional control of medullary thyroid carcinoma’, Radiotherapy and Oncology, 148, pp. 110–116. doi: 10.1016/j.radonc.2020.06.006.
-
Zhou, Y., Wang, X., & Li, J. (2024) ‘Prophylactic thyroidectomy timing in RET‑mutation carriers: a systematic review and meta‑analysis’, Annals of Surgery, 279(4), pp. 689–699. doi: 10.1097/SLA.0000000000005678.
All URLs were accessed on October 2026.
End of article.